Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer

NCT01389440 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG: Gemcitabine and Erlotinib

Sponsor

Grupo Espanol Multidisciplinario del Cancer Digestivo